Assessment of short readmissions following elective pulmonary lobectomy.


Journal

American journal of surgery
ISSN: 1879-1883
Titre abrégé: Am J Surg
Pays: United States
ID NLM: 0370473

Informations de publication

Date de publication:
01 2023
Historique:
received: 23 03 2022
revised: 31 05 2022
accepted: 31 07 2022
pmc-release: 01 01 2024
pubmed: 16 8 2022
medline: 20 12 2022
entrez: 15 8 2022
Statut: ppublish

Résumé

Reducing readmissions is critical for improving patient care and lowering costs. Despite this, few studies have assessed length of readmission following pulmonary lobectomy. Using the Healthcare Cost and Utilization Project New York State Inpatient Database, we identified adult patients undergoing elective pulmonary lobectomy (2007-2015) and assessed readmission within 30 days of hospital discharge. We analyzed the relationship between length of readmission and post-operative morbidity and mortality as well as primary diagnoses at readmission. Of 19947 included patients, 2173 (10.9%) were readmitted within 30 days. The median (IQR) length of readmission was 5 (2-8) days. Longer length of readmission was associated with significantly higher likelihood of major complication (for every 1-day increase, aOR = 1.14, 95% CI = 1.12-1.17, p < 0.001) and mortality (aOR = 1.03, 95% CI = 1.02-1.04, p < 0.001) within 90 days. Primary diagnosis codes at readmission differed significantly with length of readmission. Interventions that target short readmissions may help to prevent a proportion of readmissions following elective lung resection.

Sections du résumé

BACKGROUND
Reducing readmissions is critical for improving patient care and lowering costs. Despite this, few studies have assessed length of readmission following pulmonary lobectomy.
METHODS
Using the Healthcare Cost and Utilization Project New York State Inpatient Database, we identified adult patients undergoing elective pulmonary lobectomy (2007-2015) and assessed readmission within 30 days of hospital discharge. We analyzed the relationship between length of readmission and post-operative morbidity and mortality as well as primary diagnoses at readmission.
RESULTS
Of 19947 included patients, 2173 (10.9%) were readmitted within 30 days. The median (IQR) length of readmission was 5 (2-8) days. Longer length of readmission was associated with significantly higher likelihood of major complication (for every 1-day increase, aOR = 1.14, 95% CI = 1.12-1.17, p < 0.001) and mortality (aOR = 1.03, 95% CI = 1.02-1.04, p < 0.001) within 90 days. Primary diagnosis codes at readmission differed significantly with length of readmission.
CONCLUSIONS
Interventions that target short readmissions may help to prevent a proportion of readmissions following elective lung resection.

Identifiants

pubmed: 35970614
pii: S0002-9610(22)00497-4
doi: 10.1016/j.amjsurg.2022.07.031
pmc: PMC9900449
mid: NIHMS1866903
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

220-225

Subventions

Organisme : HSRD VA
ID : I01 HX002475
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007776
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts to report.

Références

Ann Surg. 2021 Jul 1;274(1):e70-e79
pubmed: 31469745
JAMA Netw Open. 2021 May 3;4(5):e2111613
pubmed: 34042991
J Thorac Cardiovasc Surg. 2015 Dec;150(6):1496-1504, 1505.e1-5; discussion 1504-5
pubmed: 26410004
Ann Surg. 2013 Sep;258(3):430-9
pubmed: 24022435
Ann Thorac Surg. 2015 Jun;99(6):1906-12; discussion 1913
pubmed: 25890663
Ann Thorac Surg. 2009 Dec;88(6):1749-56
pubmed: 19932230
Ann Thorac Surg. 2019 Dec;108(6):1648-1655
pubmed: 31400324
J Am Coll Surg. 2016 May;222(5):780-789.e2
pubmed: 27016905
JAMA Surg. 2018 Aug 1;153(8):719-727
pubmed: 29641833
JAMA Surg. 2018 Aug 1;153(8):764-765
pubmed: 29617521
Ann Thorac Surg. 2013 Nov;96(5):1740-5; discussion 1745-6
pubmed: 23987895
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
Ann Thorac Surg. 2016 Nov;102(5):1660-1667
pubmed: 27476821
N Engl J Med. 2017 Sep 14;377(11):1055-1064
pubmed: 28902587
Ann Thorac Surg. 2022 Aug;114(2):373-382
pubmed: 34499861
Ann Thorac Surg. 2022 Jun;113(6):1845-1852
pubmed: 34224723
Surgery. 2019 Mar;165(3):501-509
pubmed: 30638610
Ann Surg Oncol. 2021 Nov;28(12):6939-6942
pubmed: 33774770
J Am Coll Surg. 2021 Jan;232(1):27-33
pubmed: 33190785
J Clin Oncol. 2020 Oct 20;38(30):3518-3527
pubmed: 32762615
Ann Thorac Surg. 2021 Jun;111(6):1849-1857
pubmed: 33011165
J Clin Oncol. 2022 Apr 1;40(10):1033-1035
pubmed: 35073172
J Thorac Cardiovasc Surg. 2014 Nov;148(5):2261-2267.e1
pubmed: 24823283
Ann Thorac Surg. 2016 Feb;101(2):434-42; diacussion 442-3
pubmed: 26718860
Ann Thorac Surg. 2020 Mar;109(3):848-855
pubmed: 31689407

Auteurs

Brendan T Heiden (BT)

Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States. Electronic address: bheiden@wustl.edu.

Matthew Keller (M)

Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.

Bryan F Meyers (BF)

Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.

Varun Puri (V)

Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.

Margaret A Olsen (MA)

Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.

Benjamin D Kozower (BD)

Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH